Axsome Therapeutics (AXSM) to Release Quarterly Earnings on Monday

Axsome Therapeutics (NASDAQ:AXSM) is set to issue its quarterly earnings data before the market opens on Monday, May 6th. Analysts expect the company to announce earnings of ($1.22) per share for the quarter. Investors that are interested in participating in the company’s conference call can do so using this link.

Axsome Therapeutics (NASDAQ:AXSM) last announced its quarterly earnings data on Tuesday, February 20th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($1.21) by $0.48. Axsome Therapeutics had a negative net margin of 88.41% and a negative return on equity of 70.67%. The firm had revenue of $71.53 million for the quarter, compared to the consensus estimate of $70.38 million. On average, analysts expect Axsome Therapeutics to post $-4 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Axsome Therapeutics Stock Up 0.3 %

AXSM opened at $71.71 on Monday. The firm’s fifty day moving average is $75.29 and its 200 day moving average is $75.27. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.52 and a current ratio of 3.63. Axsome Therapeutics has a fifty-two week low of $55.02 and a fifty-two week high of $98.40. The stock has a market cap of $3.40 billion, a price-to-earnings ratio of -13.79 and a beta of 1.13.

Insider Transactions at Axsome Therapeutics

In related news, COO Mark L. Jacobson sold 24,662 shares of the business’s stock in a transaction on Monday, April 1st. The stock was sold at an average price of $77.24, for a total transaction of $1,904,892.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, COO Mark L. Jacobson sold 24,662 shares of Axsome Therapeutics stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $77.24, for a total transaction of $1,904,892.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Roger Jeffs sold 29,976 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $69.70, for a total transaction of $2,089,327.20. Following the completion of the transaction, the director now owns 120,756 shares in the company, valued at $8,416,693.20. The disclosure for this sale can be found here. Company insiders own 24.50% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AXSM. Robert W. Baird assumed coverage on shares of Axsome Therapeutics in a research note on Tuesday, March 19th. They set an “outperform” rating and a $108.00 target price for the company. Guggenheim raised their price target on Axsome Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a report on Wednesday, February 21st. Royal Bank of Canada upped their price objective on Axsome Therapeutics from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Tuesday, March 26th. Piper Sandler increased their price target on shares of Axsome Therapeutics from $90.00 to $113.00 and gave the company an “overweight” rating in a report on Tuesday, January 16th. Finally, UBS Group started coverage on Axsome Therapeutics in a research note on Tuesday, February 6th. They set a “buy” rating and a $111.00 price objective on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $119.67.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.